VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death

Douglas E. Brenneman, Janet Hauser, Catherine Y. Spong, Terry M. Phillips, Candace B. Pert, Michael Ruff

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) and DAPTA (D-ala-peptide T-amide, a gp120-derived octapeptide homologous to VIP) prevent neuronal cell death produced by five variants of HIV-1 (human immunodeficiency virus) envelope protein (gp120). VIP or DAPTA treatment of astrocyte cultures resulted in the release of macrophage inflammatory protein-1α (MIP-1α) and RANTES, beta chemokines known to block gp120 interactions with microglial chemokine receptors. In rat cerebral cortical cultures, gp120-induced neuronal killing was partially or completely prevented by chemokines that stimulate the CXCR4, CCR3 or CCR5 chemokine receptors. Chemokines exhibited marked differences in potency and efficacy in preventing toxicity associated with five gp120 variants (LAV/BRU, CM243, RF, SF2, and MN). RANTES had the broadest and most potent inhibition (IC50 < 3 pM for RF isolate). An octapeptide derived from RANTES also exhibited neuroprotection from gp120 (RF isolate) toxicity (IC50 = 0.3 μM). Treatment with chemokines alone had no detectable effect on neuronal cell number. However, antiserum to MIP-1α produced neuronal cell death that was prevented by co-treatment with MIP-1α, suggesting that this endogenous chemokine exerts a tonic regulation important to neuronal survival. The neuroprotective action of VIP on gp120 was attenuated by co- treatment with anti-MIP-1α. These studies suggest that the neuroprotective action of VIP is linked in part to its release of MIP-1α. Furthermore, neuroprotection produced by chemokines is dependent on both the type of chemokine and the variant structure of gp120 and may be relevant to drug strategies for the treatment of AIDS dementia.

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalBrain Research
Volume838
Issue number1-2
DOIs
StatePublished - Aug 14 1999
Externally publishedYes

Fingerprint

Vasoactive Intestinal Peptide
Chemokines
Macrophage Inflammatory Proteins
HIV-1
Chemokine CCL5
Chemokine Receptors
Inhibitory Concentration 50
Human Immunodeficiency Virus env Gene Products
Cell Death
CCR5 Receptors
Chemokine CCL4
CC Chemokines
Astrocytes
Dementia
peptide T amide
Immune Sera
Acquired Immunodeficiency Syndrome
Anti-Inflammatory Agents
Cell Count
Pharmaceutical Preparations

Keywords

  • Acquired immunodeficiency syndrome
  • Chemokine
  • Gp120
  • Peptide T
  • Secretion
  • Vasoactive intestinal peptide

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. / Brenneman, Douglas E.; Hauser, Janet; Spong, Catherine Y.; Phillips, Terry M.; Pert, Candace B.; Ruff, Michael.

In: Brain Research, Vol. 838, No. 1-2, 14.08.1999, p. 27-36.

Research output: Contribution to journalArticle

Brenneman, Douglas E. ; Hauser, Janet ; Spong, Catherine Y. ; Phillips, Terry M. ; Pert, Candace B. ; Ruff, Michael. / VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. In: Brain Research. 1999 ; Vol. 838, No. 1-2. pp. 27-36.
@article{2da70305e96740198d7771fbc54f1e24,
title = "VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death",
abstract = "Vasoactive intestinal peptide (VIP) and DAPTA (D-ala-peptide T-amide, a gp120-derived octapeptide homologous to VIP) prevent neuronal cell death produced by five variants of HIV-1 (human immunodeficiency virus) envelope protein (gp120). VIP or DAPTA treatment of astrocyte cultures resulted in the release of macrophage inflammatory protein-1α (MIP-1α) and RANTES, beta chemokines known to block gp120 interactions with microglial chemokine receptors. In rat cerebral cortical cultures, gp120-induced neuronal killing was partially or completely prevented by chemokines that stimulate the CXCR4, CCR3 or CCR5 chemokine receptors. Chemokines exhibited marked differences in potency and efficacy in preventing toxicity associated with five gp120 variants (LAV/BRU, CM243, RF, SF2, and MN). RANTES had the broadest and most potent inhibition (IC50 < 3 pM for RF isolate). An octapeptide derived from RANTES also exhibited neuroprotection from gp120 (RF isolate) toxicity (IC50 = 0.3 μM). Treatment with chemokines alone had no detectable effect on neuronal cell number. However, antiserum to MIP-1α produced neuronal cell death that was prevented by co-treatment with MIP-1α, suggesting that this endogenous chemokine exerts a tonic regulation important to neuronal survival. The neuroprotective action of VIP on gp120 was attenuated by co- treatment with anti-MIP-1α. These studies suggest that the neuroprotective action of VIP is linked in part to its release of MIP-1α. Furthermore, neuroprotection produced by chemokines is dependent on both the type of chemokine and the variant structure of gp120 and may be relevant to drug strategies for the treatment of AIDS dementia.",
keywords = "Acquired immunodeficiency syndrome, Chemokine, Gp120, Peptide T, Secretion, Vasoactive intestinal peptide",
author = "Brenneman, {Douglas E.} and Janet Hauser and Spong, {Catherine Y.} and Phillips, {Terry M.} and Pert, {Candace B.} and Michael Ruff",
year = "1999",
month = "8",
day = "14",
doi = "10.1016/S0006-8993(99)01644-3",
language = "English (US)",
volume = "838",
pages = "27--36",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death

AU - Brenneman, Douglas E.

AU - Hauser, Janet

AU - Spong, Catherine Y.

AU - Phillips, Terry M.

AU - Pert, Candace B.

AU - Ruff, Michael

PY - 1999/8/14

Y1 - 1999/8/14

N2 - Vasoactive intestinal peptide (VIP) and DAPTA (D-ala-peptide T-amide, a gp120-derived octapeptide homologous to VIP) prevent neuronal cell death produced by five variants of HIV-1 (human immunodeficiency virus) envelope protein (gp120). VIP or DAPTA treatment of astrocyte cultures resulted in the release of macrophage inflammatory protein-1α (MIP-1α) and RANTES, beta chemokines known to block gp120 interactions with microglial chemokine receptors. In rat cerebral cortical cultures, gp120-induced neuronal killing was partially or completely prevented by chemokines that stimulate the CXCR4, CCR3 or CCR5 chemokine receptors. Chemokines exhibited marked differences in potency and efficacy in preventing toxicity associated with five gp120 variants (LAV/BRU, CM243, RF, SF2, and MN). RANTES had the broadest and most potent inhibition (IC50 < 3 pM for RF isolate). An octapeptide derived from RANTES also exhibited neuroprotection from gp120 (RF isolate) toxicity (IC50 = 0.3 μM). Treatment with chemokines alone had no detectable effect on neuronal cell number. However, antiserum to MIP-1α produced neuronal cell death that was prevented by co-treatment with MIP-1α, suggesting that this endogenous chemokine exerts a tonic regulation important to neuronal survival. The neuroprotective action of VIP on gp120 was attenuated by co- treatment with anti-MIP-1α. These studies suggest that the neuroprotective action of VIP is linked in part to its release of MIP-1α. Furthermore, neuroprotection produced by chemokines is dependent on both the type of chemokine and the variant structure of gp120 and may be relevant to drug strategies for the treatment of AIDS dementia.

AB - Vasoactive intestinal peptide (VIP) and DAPTA (D-ala-peptide T-amide, a gp120-derived octapeptide homologous to VIP) prevent neuronal cell death produced by five variants of HIV-1 (human immunodeficiency virus) envelope protein (gp120). VIP or DAPTA treatment of astrocyte cultures resulted in the release of macrophage inflammatory protein-1α (MIP-1α) and RANTES, beta chemokines known to block gp120 interactions with microglial chemokine receptors. In rat cerebral cortical cultures, gp120-induced neuronal killing was partially or completely prevented by chemokines that stimulate the CXCR4, CCR3 or CCR5 chemokine receptors. Chemokines exhibited marked differences in potency and efficacy in preventing toxicity associated with five gp120 variants (LAV/BRU, CM243, RF, SF2, and MN). RANTES had the broadest and most potent inhibition (IC50 < 3 pM for RF isolate). An octapeptide derived from RANTES also exhibited neuroprotection from gp120 (RF isolate) toxicity (IC50 = 0.3 μM). Treatment with chemokines alone had no detectable effect on neuronal cell number. However, antiserum to MIP-1α produced neuronal cell death that was prevented by co-treatment with MIP-1α, suggesting that this endogenous chemokine exerts a tonic regulation important to neuronal survival. The neuroprotective action of VIP on gp120 was attenuated by co- treatment with anti-MIP-1α. These studies suggest that the neuroprotective action of VIP is linked in part to its release of MIP-1α. Furthermore, neuroprotection produced by chemokines is dependent on both the type of chemokine and the variant structure of gp120 and may be relevant to drug strategies for the treatment of AIDS dementia.

KW - Acquired immunodeficiency syndrome

KW - Chemokine

KW - Gp120

KW - Peptide T

KW - Secretion

KW - Vasoactive intestinal peptide

UR - http://www.scopus.com/inward/record.url?scp=0033554205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033554205&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(99)01644-3

DO - 10.1016/S0006-8993(99)01644-3

M3 - Article

C2 - 10446313

AN - SCOPUS:0033554205

VL - 838

SP - 27

EP - 36

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -